Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Red Cat Holdings (RCAT): Breaking Down the $16 Analyst Target and +350% Upside Path

Red Cat Holdings (RCAT): Breaking Down the $16 Analyst Target and +350% Upside Path

Key Takeaways

  • The central target of $16 is the arithmetic mean of seven current analyst price targets reviewed for Red Cat Holdings, Inc. (RCAT), which range from roughly $6 to $25.
  • With the stock at a latest closing price of about $3.53 (November 16, 2026), reaching $16 would require a move of roughly 350% — a very large gain by any standard.
  • Analysts broadly rate the shares Buy or Strong Buy, but the wide $6–$25 spread reflects deep disagreement over execution, funding, and contract timing.
  • The strongest supports are the Black Widow U.S. Army program, international orders, and a proposed acquisition of Steyr Motors AG.
  • The biggest risks are a withdrawn full-year revenue outlook, a Drone Dominance 2 setback, sharply negative margins, and dilution.
  • You can review Major News, Today's Price Move, the Forecast, and Earnings for RCAT on dedicated pages to track developments around this target.
  • Explore Trending AI Robots for AI-driven tools that monitor stocks and ETFs for changing market conditions.

Analyst Price Targets and Consensus View

Red Cat Holdings is a Utah-based maker of small and tactical uncrewed aircraft systems (UAS) for defense and national security customers. Across seven identifiable, non-stale analyst targets, the individual price objectives are $6 (Piper Sandler, Clarke Jeffries, October 23, 2026), $19 (Clear Street, Brian Dobson, October 19), $15 (Evercore ISI, Amit Daryanani, October 14), $13 (Northland Securities, Michael Latimore, September 17), $25 (Roth MKM, Craig Irwin, August 11), $15 (Needham, Austin Bohlig, August 7), and $20 (H.C. Wainwright, Amit Dayal, August 7). Their arithmetic mean is about $16.14, rounded to a $16 central target.

The dispersion is unusually wide — from $6 to $25 — signaling a genuine split between cautious analysts focused on near-term execution and bullish analysts focused on multi-year defense demand. The average analyst price target clusters around $15.60 to $16.30 depending on the source and look-back window, consistent with the $16 figure used here. Recent action has been downward: Piper Sandler cut its target from $9 to $6 in October while maintaining a Neutral rating, while several Buy-rated firms have kept targets between $13 and $25. This is not a tight consensus, and the mean should be read as a reference point, not a forecast. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

The shares closed at about $3.53 on November 16, 2026, down roughly 7% in the session, and slid further in after-hours trading following a third-quarter earnings miss. The stock sits just above its 52-week range low of about $3.25, far below its 52-week high near $18.78. Reaching $16 therefore implies a gain of roughly 350%, a very large move that would require a fundamental re-rating, not a routine rally.

The path would need to run through restored revenue visibility. In the quarter ended September 30, 2026, revenue of about $11.8 million missed a consensus estimate near $42 million, and the company withdrew its full-year 2026 revenue guidance. The stock price target of $16 implicitly assumes a return to growth, margin recovery, and renewed confidence in contract awards — conditions that are not currently priced in.

What Could Support a Move Toward the Target

  • The U.S. Army selected the company's Black Widow drone for the Short Range Reconnaissance (SRR) production program, and deliveries to the Japan Ground Self-Defense Force have begun, providing a foundation of real orders.
  • Management is expanding manufacturing capacity, including the Blue Ops maritime facility in Georgia, and announced a proposed acquisition of Steyr Motors AG to broaden its product base.
  • The company held roughly $240 million in cash at the end of September, offering runway to fund operations while it works through execution issues.
  • Longer term, rising defense spending on autonomous systems supports the strategic case that underpins the highest analyst targets.

What Could Prevent the Target From Being Reached

  • The withdrawal of full-year 2026 revenue guidance and a gross margin that fell to about 0.6% in the latest quarter undercut the profitability assumptions behind higher targets.
  • The FANG FPV platform was not selected as a finalist in the Drone Dominance 2 competition, removing a near-term revenue catalyst.
  • The share count has risen sharply — up roughly 42% over the past year — reflecting dilution that weighs on per-share valuation.
  • Ongoing operating losses, cash burn, and a stock near 52-week lows keep valuation anchored by execution risk rather than growth optionality.

Technical Levels and Market Structure

RCAT has been in a sustained downtrend, down more than 50% over the trailing 12 months and roughly 63% over three months. The 52-week low near $3.25 is the key support level, and after-hours trading following the earnings report briefly pushed the shares below it. On the upside, resistance is likely to emerge around the $6 level — the lowest current analyst target and a prior support-turned-resistance zone — followed by the $9–$10 area and the cluster of targets near $15. A durable move toward $16 would require reclaiming and holding well above these levels, which have not been tested recently. From what I see, monitoring these levels with AI-driven pattern tools can add useful context to the chart setup.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though the targets used here were issued between August and October 2026 and carry differing assumptions. Investors should watch whether the company restores or revises its revenue outlook, the pace of Army and international deliveries, gross margin trends, any closing terms for the Steyr Motors acquisition, further analyst target revisions, and capital-raising activity given the recent share count growth. Macro drivers such as U.S. defense budget execution and interest-rate expectations also matter for a pre-profit, high-beta growth stock.

Final Assessment

The $16 central target is an average of seven current analyst price targets spanning $6 to $25, and it sits roughly 350% above the latest closing price near $3.53 — an enormous required move. Support comes from a genuine Army program, early international sales, and a healthy cash balance, while the bearish case rests on withdrawn guidance, a missed competition, negative margins, and dilution. The wide analyst range shows there is no clean consensus, and the near-term trend and technical structure remain firmly against the stock. Whether RCAT approaches $16 depends on a credible return to revenue growth and profitability; the next earnings print, guidance updates, and analyst revisions will be the most important signposts. No outcome is guaranteed, and this is not a recommendation to buy or sell.

Using AI Daily Buy/Sell Signals for Ongoing Monitoring

In my own workflow, Tickeron's AI Daily Buy/Sell Signals have proven useful for tracking volatile names like RCAT. These AI-driven signals continuously scan thousands of stocks and ETFs, delivering Buy, Sell, or Hold alerts based on technical shifts and market conditions. For a name with this kind of execution risk and momentum swings, the tool helps surface potential changes earlier than manual chart reviews alone, allowing for more disciplined position management.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: RCAT

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


RCAT sees MACD Histogram crosses below signal line

RCAT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 17, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In 36 of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RCAT as a result. In 67 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for RCAT entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +32.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCAT advanced for three days, in 233 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

RCAT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.309) is normal, around the industry mean (5.050). P/E Ratio (-5.050) is within average values for comparable stocks, (17.247). Projected Growth (PEG Ratio) (0.060) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (11.820) is also within normal values, averaging (18.367).

The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. RCAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.

Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Virgin Galactic Holdings (NYSE:SPCE).

Industry description

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

Market Cap

The average market capitalization across the Aerospace & Defense Industry is 36.83B. The market cap for tickers in the group ranges from 4.49 to 1.77T. SPCX holds the highest valuation in this group at 1.77T. The lowest valued company is BDRPF at 4.49.

High and low price notable news

The average weekly price growth across all stocks in the Aerospace & Defense Industry was -11%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -32%. HAWK experienced the highest price growth at 20%, while SPCE experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the Aerospace & Defense Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 40% and the average quarterly volume growth was -44%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 54
Price Growth Rating: 63
SMR Rating: 78
Profit Risk Rating: 78
Seasonality Score: -10 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry AerospaceDefense

Industry
N/A
Address
2800 South West Temple
Phone
+1 800 466-9152
Employees
244
Web
https://www.redcat.red
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
KLAR dropped -4.84% to $13.75 from Wednesday's close of $14.45, with the decline occurring during Thursday's regular session. JPMorgan downgraded the shares to Hold from Overweight and cut its price target to $17 from $20 in a note published before the open, extending a run of post-earnings target reductions.